We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-14.52%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$230M
AUM Growth
-$31.4M
Cap. Flow
+$15.3M
Cap. Flow %
6.65%
Top 10 Hldgs %
97.77%
Holding
14
New
1
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.21M
2
BBIO icon
BridgeBio Pharma
BBIO
+$4.77M
3
TECX
Tectonic Therapeutic
TECX
+$2.29M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$116M 50.4%
3,989,412
+153,690
+4% +$4.77M
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$55M 23.98%
1,123,630
– –
TECX
3
Tectonic Therapeutic
TECX
$529M
$15.7M 6.84%
84,148
+9,725
+13% +$2.29M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$9.6M 4.18%
+875,000
New +$8.21M
BCEL
5
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.42M 2.8%
387,653
– –
SYRE icon
6
Spyre Therapeutics
SYRE
$8.54B
$6.02M 2.62%
51,646
– –
RCUS icon
7
Arcus Biosciences
RCUS
$3.55B
$4.63M 2.02%
333,333
– –
VIRX
8
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.19M 1.83%
288,571
– –
MRKR icon
9
Marker Therapeutics
MRKR
$18.8M
$3.8M 1.66%
200,000
– –
OBSV
10
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.34M 1.46%
1,386,338
– –
VRNA
11
DELISTED
Verona Pharma
VRNA
$1.83M 0.8%
443,596
– –
ZSAN
12
DELISTED
Zosano Pharma Corporation
ZSAN
$1.53M 0.67%
77,664
– –
NBRV
13
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.1M 0.48%
7,641
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$726M
$660K 0.29%
634,455
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Aisling Capital Management held 14 positions worth $230M, down 12% from $261M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management deployed $15.3M of net new capital in Q1 2020, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 875,000 shares worth $9.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q1 2020 buy was Syndax Pharmaceuticals: 875,000 shares worth $9.6M.
  • Aisling Capital Management added most to BridgeBio Pharma in Q1 2020, an estimated $4.77M increase.
  • Aisling Capital Management's ten largest holdings make up 98% of its $230M portfolio in Q1 2020.
  • Aisling Capital Management opened 1 new position and closed 0 in Q1 2020.
  • Aisling Capital Management's portfolio value fell 12% quarter-over-quarter to $230M.

Based on Aisling Capital Management's 13F filing for Q1 2020, filed 11 May 2020.